Qsemble Capital Management LP Invests $609,000 in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Qsemble Capital Management LP purchased a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 7,579 shares of the medical equipment provider's stock, valued at approximately $609,000.

Several other institutional investors and hedge funds have also modified their holdings of LNTH. Vanguard Group Inc. grew its stake in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider's stock worth $458,271,000 after buying an additional 389,828 shares in the last quarter. Westfield Capital Management Co. LP lifted its holdings in shares of Lantheus by 25.3% in the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider's stock worth $121,867,000 after acquiring an additional 394,837 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Lantheus by 595.3% in the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider's stock worth $92,316,000 after acquiring an additional 1,269,900 shares during the last quarter. Reinhart Partners LLC. lifted its holdings in shares of Lantheus by 8.4% in the first quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider's stock worth $91,517,000 after acquiring an additional 114,110 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Lantheus by 0.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 839,957 shares of the medical equipment provider's stock worth $52,077,000 after acquiring an additional 7,590 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on LNTH. Redburn Atlantic initiated coverage on shares of Lantheus in a report on Tuesday, September 3rd. They issued a "buy" rating and a $175.00 target price for the company. Leerink Partners raised their price objective on shares of Lantheus from $106.00 to $127.00 and gave the company an "outperform" rating in a report on Thursday, July 11th. Truist Financial dropped their price objective on shares of Lantheus from $141.00 to $135.00 and set a "buy" rating for the company in a report on Thursday, August 1st. JMP Securities lowered their price target on shares of Lantheus from $130.00 to $125.00 and set a "market outperform" rating for the company in a report on Thursday, August 1st. Finally, B. Riley raised their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a "buy" rating in a report on Thursday, July 25th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of "Moderate Buy" and an average target price of $126.00.

Insider Activity at Lantheus

In related news, President Paul Blanchfield sold 2,000 shares of Lantheus stock in a transaction on Thursday, August 8th. The shares were sold at an average price of $96.39, for a total value of $192,780.00. Following the completion of the sale, the president now owns 98,980 shares of the company's stock, valued at approximately $9,540,682.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Lantheus news, President Paul Blanchfield sold 2,000 shares of the firm's stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $96.39, for a total transaction of $192,780.00. Following the transaction, the president now directly owns 98,980 shares in the company, valued at approximately $9,540,682.20. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Gary J. Pruden sold 12,530 shares of the firm's stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $95.04, for a total value of $1,190,851.20. Following the transaction, the director now owns 11,978 shares in the company, valued at $1,138,389.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 40,852 shares of company stock valued at $3,922,001. 1.50% of the stock is owned by company insiders.

Lantheus Trading Up 1.5 %

Shares of LNTH stock traded up $1.52 during trading hours on Friday, hitting $105.55. 1,119,849 shares of the company were exchanged, compared to its average volume of 1,028,340. The firm has a market cap of $7.33 billion, a P/E ratio of 16.11 and a beta of 0.50. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a 50 day simple moving average of $104.91 and a two-hundred day simple moving average of $82.63.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Wednesday, July 31st. The medical equipment provider reported $1.61 EPS for the quarter, missing the consensus estimate of $1.68 by ($0.07). The company had revenue of $394.10 million for the quarter, compared to analyst estimates of $382.12 million. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The business's quarterly revenue was up 22.5% compared to the same quarter last year. During the same period last year, the business earned $1.40 EPS. Equities analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.